期刊文献+

高血压患者OGTT试验结果分析 被引量:1

Analysis of OGTT results in hypertension patients
下载PDF
导出
摘要 目的探讨高血压与胰岛素抵抗的关系。方法 1133例做口服葡萄糖耐量试验(OGTT)的研究对象,排除360例不符合标准的患者后,剩余773例分为高血压(93例)与非高血压(680例)两组,再分别把体质量指数(BMI)<24 kg/m2视分为正常体重组,把BMI≥24 kg/m2定为肥胖组;OGTT试验中,检测各时相的血糖、胰岛素、C肽数值并进行统计分析。结果 BMI≥24 kg/m2的高血压或非高血压者,其血糖、胰岛素、C肽均值分别高于BMI<24 kg/m2者(P<0.05)。BMI<24 kg/m2的高血压与非高血压者对比,糖负荷后1.0 h高血压患者血糖显著高于非高血压者(P>0.05)。BMI≥24 kg/m2的高血压患者,除3.0 h血糖外,其余时相血糖、胰岛素、C肽与非高血压组比较,差异有统计学意义(P<0.05)。结论肥胖合并高血压患者有明显的"三高",即高血糖、高胰岛素、高C肽血症。 Objective To investigate relationship between hypertension and insulin resistance. Methods There were 1133 patients receiving oral glucose tolerance test(OGTT) as study subjects, and 360 unqualified cases among them were eliminated. The other 773 cases were divided into hypertension group(93 cases) and non-hypertension group(680 cases). Patients with body mass index(BMI) 〈24 kg/m^2 were taken as normal weight group, and those with BMI ≥ 24 kg/m^2 as obesity group. Detections were made on blood glucose, insulin, and C-peptide in different time points for statistical analysis. Results Patients with BMI ≥ 24 kg/m^2 in both hypertension and non-hypertension groups had higher blood glucose, insulin, and C-peptide than those with BMI〈 24 kg/m^2(P〉0.05). Patients with BMI〈 24 kg/m^2 in hypertension group had higher 1.0 h blood glucose after glucose load than those in non-hypertension group(P〈0.05). Patients with BMI ≥ 24 kg/m^2 in hypertension group had statistically significant differences of blood glucose, insulin, and C-peptide with non-hypertension group, with exception of 3.0 h blood glucose(P〈0.05). Conclusion Obesity complicated with hypertension patients have obvious high levels of blood glucose, insulin, and C-peptide.
出处 《中国实用医药》 2015年第25期19-20,共2页 China Practical Medicine
关键词 高血压 口服葡萄糖耐量试验 高胰岛素血症 胰岛素抵抗 Hypertension Oral glucose tolerance test Hyperinsulinemia Insulin resistance
  • 相关文献

参考文献5

二级参考文献22

  • 1贾伟平,潘洁敏,陈蕾,吴元民,陆俊茜,项坤三.空腹血糖受损切点变化与糖尿病及心脑血管事件风险的关系——上海华阳社区40岁以上人群的随访研究[J].中华内分泌代谢杂志,2004,20(5):392-395. 被引量:86
  • 2刘娟,李光伟,潘孝仁.胰岛素抵抗与冠心病危险因素的关系[J].中华心血管病杂志,1995,23(1):46-49. 被引量:21
  • 3van Genugten RE, van Raalte DH, Diamant M. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide. Diabetes Res Clin Pract, 2009, 86 ( Suppl 1 ) : $26-S34.
  • 4Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev, 2012,33 : 187-215.
  • 5Nisoli E, Clementi E, Paolucci C, et al. Mitochondrial biogenesis in mammals : the role of endogenous nitric oxide. Science, 2003,299 :896~899.
  • 6Fruhbeck G, Becerril S, Sainz N, et al. BAT: a new target for human obesity? Trends Pharmacol Sci, 2009,30:387-396.
  • 7Cannon B, Nedergaard J. Cultures of adipose precursor cells from brown adipose tissue and of clonal brown-adipocyte-like cell lines. Methods Mol Biol, 200l, 155:213-224.
  • 8Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev, 2004,84:277-359.
  • 9Seale P, Bjork B, Yang W, et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature, 2008,454:961-967.
  • 10Puigserver P. Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1 -alpha. Int Obes( Lond), 2005,29 ( Suppl 1 ) : S5-S9.

共引文献58

同被引文献9

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部